These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22507929)

  • 21. Diabetes is Associated with Severe Adverse Events in Multidrug-Resistant Tuberculosis.
    Muñoz-Torrico M; Caminero-Luna J; Migliori GB; D'Ambrosio L; Carrillo-Alduenda JL; Villareal-Velarde H; Torres-Cruz A; Flores-Vergara H; Martínez-Mendoza D; García-Sancho C; Centis R; Salazar-Lezama MÁ; Pérez-Padilla R
    Arch Bronconeumol; 2017 May; 53(5):245-250. PubMed ID: 28089216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antituberculosis drug-induced hepatotoxicity is uncommon in Tanzanian hospitalized pulmonary TB patients.
    Tostmann A; van den Boogaard J; Semvua H; Kisonga R; Kibiki GS; Aarnoutse RE; Boeree MJ
    Trop Med Int Health; 2010 Feb; 15(2):268-72. PubMed ID: 20409289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Time to revise WHO-recommended definitions of MDR-TB treatment outcomes.
    Lange C; van Leth F; Mitnick CD; Dheda K; Günther G
    Lancet Respir Med; 2018 Apr; 6(4):246-248. PubMed ID: 29595505
    [No Abstract]   [Full Text] [Related]  

  • 25. Standardised second-line treatment of multidrug-resistant tuberculosis during pregnancy.
    Tabarsi P; Moradi A; Baghaei P; Marjani M; Shamaei M; Mansouri N; Chitsaz E; Farnia P; Mansouri D; Masjedi M; Velayati A
    Int J Tuberc Lung Dis; 2011 Apr; 15(4):547-50. PubMed ID: 21396217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: A cohort study.
    Wondwossen Abera ; Waqtola Cheneke ; Gemeda Abebe
    Int J Mycobacteriol; 2016 Mar; 5(1):14-20. PubMed ID: 26927985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mortality among MDR-TB cases: comparison with drug-susceptible tuberculosis and associated factors.
    Chung-Delgado K; Guillen-Bravo S; Revilla-Montag A; Bernabe-Ortiz A
    PLoS One; 2015; 10(3):e0119332. PubMed ID: 25790076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative.
    Nathanson E; Gupta R; Huamani P; Leimane V; Pasechnikov AD; Tupasi TE; Vink K; Jaramillo E; Espinal MA
    Int J Tuberc Lung Dis; 2004 Nov; 8(11):1382-4. PubMed ID: 15581210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MDR-TB has new drug foe after fast-track approval.
    Voelker R
    JAMA; 2013 Feb; 309(5):430. PubMed ID: 23385248
    [No Abstract]   [Full Text] [Related]  

  • 30. Adverse effects of multidrug-resistant tuberculosis treatment with a standardized regimen: a report from Iran.
    Baghaei P; Tabarsi P; Dorriz D; Marjani M; Shamaei M; Pooramiri MV; Mansouri D; Farnia P; Masjedi M; Velayati A
    Am J Ther; 2011; 18(2):e29-34. PubMed ID: 20019591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design.
    Mok JH; Kang BH; Lee T; Lee HK; Jang HJ; Cho YJ; Jeon D
    J Korean Med Sci; 2017 Apr; 32(4):636-641. PubMed ID: 28244290
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
    Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA
    Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictor of multidrug resistant tuberculosis in southwestern part of Ethiopia: a case control study.
    Gobena D; Ameya G; Haile K; Abreha G; Worku Y; Debela T
    Ann Clin Microbiol Antimicrob; 2018 Jul; 17(1):30. PubMed ID: 29970076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004.
    Bloss E; Kuksa L; Holtz TH; Riekstina V; Skripconoka V; Kammerer S; Leimane V
    Int J Tuberc Lung Dis; 2010 Mar; 14(3):275-81. PubMed ID: 20132617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multidrug-resistant tuberculosis: treatment is empirical, for want of robust trials.
    Prescrire Int; 2014 Oct; 23(153):245-6. PubMed ID: 25964976
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multidrug-resistant TB in Zambia: review of national data from 2000 to 2011.
    Kapata N; Chanda-Kapata P; Bates M; Mwaba P; Cobelens F; Grobusch MP; Zumla A
    Trop Med Int Health; 2013 Nov; 18(11):1386-91. PubMed ID: 24033538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis.
    Kunkel A; Cobelens FG; Cohen T
    PLoS Med; 2016 Oct; 13(10):e1002142. PubMed ID: 27727274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Rational use of hepato-protectants in the prophylaxis and treatment of anti-tuberculosis drug-induced hepatotoxicity].
    Gu J; Xiao HP
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Oct; 36(10):767-9. PubMed ID: 24433806
    [No Abstract]   [Full Text] [Related]  

  • 39. Hearing loss in children treated for multidrug-resistant tuberculosis.
    Seddon JA; Thee S; Jacobs K; Ebrahim A; Hesseling AC; Schaaf HS
    J Infect; 2013 Apr; 66(4):320-9. PubMed ID: 22960077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A case of hyperacute hepatotoxicity in response to tuberculosis therapy.
    Hercus CG; Khoo JK; Jones TE
    Int J Tuberc Lung Dis; 2012 Dec; 16(12):1709-10. PubMed ID: 23131275
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.